BioCorRx Inc (OTCMKTS:BICX) Stock In Focus After Interim Positive Results of Phase 1 Clinical Trial

March 8, 2023

Clinical stage developer and innovative treatment programs providing company for substance abuse problems BioCorRx Inc (OTCMKTS:BICX) is a company that may well be worth looking into at this point in time. The company announced interim positive pharmacokintetic and safety results from the Phase 1 clinical trial of its product BICX104. The product in question is an implantable naltrexone pellet. Trading Data On Tuesday, BICX stock fell 0.32% to $1.5550 with…